Member Info for crumbs

We can but hope.... thanks for the link.... Sundays reading sorted :)

No Jedd Wolchok was part of project blueprint

Blog... a nice little article

; Our Science Surgery series answers your cancer science questions.

Millie asked us on Instagram: “Why doesn’t the immune system attack cancer cells?”

“Our immune system does attack cancer cells,” says Professor Tim Elliott, a Cancer Research UK-funded immunologist from the University of Southampton.

“It’s recognising and destroying little cancers as they develop all the time. If we didn’t have an immune system, then we would be developing cancer a lot more often.”

This is because the process of cell division isn’t perfect. The rate at which some cells grow and divide means errors can happen and cells become damaged

.'https://scienceblog.cancerresearchuk.org/2019/02/28/science-surgery-why-doesnt-the-immune-system-attack-cancer-cells/

I see it as the new device is a commercial device and scancell see SCIB1 as a commercial product....Simple as that

As fits in with the whole investing topic... 'The greatest investor you've never heard of' .....Immunotheraphy as a market is very much like the tech boom... it is a revolutionary market that has hardly begun it's products will create their own markets that do not exist at the moment by simple fact that cancer rates keep going up and an all too common outcome is cancers become untreatable so if you can treat the untreatable you create a whole new market... anyways the article

https://www.forbes.com/sites/maddieberg/2019/02/19/the-greatest-investor-youve-never-heard-of-an-optometrist-who-beat-the-odds-to-become-a-billionaire/#40ae033122e8

Tying in nicely for that BioNtech NASDAQ IPO...you would think they would want a cell therapy trial/s for part of their IPO prospectus too... certainly they have been recruiting more and more staff

Nice link C7... and congrats on the win lol....
As for anything else... my thinking is never to try to attach dates to anything happening here:) .... it's why GC got us all so excited lol it had a real date attached... that, of course, is not to say nothing will happen just they happen when they happen and always later than hoped for! .... but on that article... it is interesting that LD describes that at the calc event as an 'older' technology :) seeing as really it is still quite new and a bit away from commercialisation BioNtech/Genetech are going all at it though

Published online on the 20th Feb 2019 and 107 viewings already which is not bad for a scientific paper .... and I think shows there is some serious interest in moditope.

https://www.tandfonline.com/doi/full/10.1080/2162402X.2019.1576490

'BioNTech will have the exclusive option to enter into a licence agreement for the development of cell receptor based therapeutics that are specific to Modi-1 epitopes.'

'The Company is continuing discussions on potential commercial partnership discussions for the Moditope® platform alongside its clinical development plans, with multiple partnering discussions in progress.'

'Professor Lindy Durrant who commented: "Samantha will be invaluable in immunological design of the upcoming trials and spearheading the new TCR therapeutics and I am very excited to add such an experienced scientist to the team."'

Maybe because a commercial deal is on the way.... just maybe :)

I seem to remember Lindy has a couple of UK based events coming up.... It seems she prefers going local which I understand

Exactly... which is why the 'serendipitous' moditope discovery is so exciting as it seemingly kickstarts a natural pre-existing mechanism which is being suppressed but once it kicks in it can't be stopped in fact the more cancer tries to stop it the more it activates it... boom!
no need for inhibitors or re-engineering without knowing what actions and reactions you might trigger.... really quite simple

Nice vids T cells against cancer cells
https://nanolive.ch/immuno-oncology-t-cells-targeting-and-killing-cancer-cells/

Think... one therapeutic dose of moditope and 3 days later late stage heavy burden tumours destroyed...

'These cytotoxic CD4 T cells really are amazing' L Durrant....... never seen anything like it before... well when you watch these vids you can really appreciate the potential of moditope...

On from Mercks Keytruda combo deal yesterday:

'Pfizer (NYSE:PFE) had big expectations for Inlyta when it launched in 2012. Over the past few years, though, it's fallen out of favor as new, more effective treatments set up camp in its neighborhood.

Despite being unremarkable as a monotherapy, it turns out Inlyta added to Keytruda from Merck & Co. (NYSE:MRK) gives new kidney cancer patients a much better chance at long-term survival than standard care. Here's what's behind the most unlikely Cinderella story the biopharma space has seen in a long time.'

https://www.fool.com/investing/2019/02/19/pfizers-forgotten-cancer-pill-is-about-to-become-i.aspx

Apparently, BDO is the number one AIM companies auditor ... I'm not sure it means anything good or bad...we would only know that if reasons were given for the change and they have not been.... nice to see some blue though :)

Have tweeted it...
https://twitter.com/trinity_delta/status/1098580557255069696

It is interesting that they not only put @scancellpharma but also @BioNtech_Group and also @TransgeneSA

It might also show that area is heating up... the battle for combos is on!

'even thou its pipeline quality is 10 x immunedesign ...'

If the moditope mechanism works in human trials as well as preclinical humanised mice models and donated human blood both from healthy and cancer patient donors .....then I would say scancells pipeline qualitywcould be 10 x Mercks :p

I dunno... could be and yeah reckon that one is a buy...

Those 200k's again... just waiting for C7 :)

Of I/O courtroom drama for a Sunday... the battle over PD1 patents... something 'landgrab' scancell wouldn't have to worry about :)

'Dr. Honjo's side includes the pharma giant Bristol-Myers Squibb, which now holds the licenses that control the use of those patents. Honjo himself took the stand for many hours of confident and sometimes slightly testy testimony. He argued that no, he got no significant help from his American colleagues.

One thing is sure: The stakes are high.

"The patents that are currently issued to Professor Honjo are probably worth billions of dollars," said professor Jake Sherkow of New York Law School, an expert on patent disputes in the life sciences.

The patents at issue relate to multiple immunotherapy drugs that are each selling for a couple of billion dollars a year, he said.

"We've got Keytruda, we've got Opdivo, we've got Libtayo, we've got Tecentriq, we've got Bavencio, we've got Imfinzi — all of these drugs are, if not blockbuster drugs, at least pretty close to it," he said. "So that's what this dispute is all about."
https://www.wbur.org/commonhealth/2019/02/15/immunotherapy-patent-billions-suit-dana-farber